53997
document
A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders . Ginkgo biloba has been reported to affect the neurotransmitter system and to have antioxidant properties that could impact the pathogenesis of Autism Spectrum Disorder . Based on these studies , we decided to assess the effectiveness of Ginkgo biloba extract ( Ginko T.D. , Tolidaru , Iran ) as an adjunctive agent to risperidone in the treatment of autism . Forty-seven outpatients with a DSM-IV-TR diagnosis of autism ages between 4 and 12 years were assigned to this double blinded clinical trial and were randomly divided into two groups . One group received risperidone plus Ginko T.D and the other received risperidone plus placebo . The dose of risperidone was 1-3 mg/day and the dose of Ginko T.D . was 80 mg/day for patients under 30 kg and 120 mg/day for patients above 30 kg . Patients were assessed using Aberrant Behavior Checklist-Community ( ABC-C ) rating scale and the side effect check list every 2 weeks until the endpoint . None of the 5 subscales of ABC-C rating scale showed significant differences between the two groups . Incidents of side effects were not significantly different between the two groups . Adding Ginkgo biloba to risperidone did not affect the treatment outcome of ADs . Nevertheless , further observations are needed to confirm this result .
53998
Intervention_Control
placebo
53999
Intervention_Pharmacological
Ginkgo biloba
54000
Intervention_Pharmacological
risperidone
54001
Intervention_Pharmacological
Ginkgo biloba
54002
Intervention_Pharmacological
risperidone plus Ginko T.D and the
54003
Intervention_Control
placebo
54004
Intervention_Pharmacological
risperidone
54005
Intervention_Pharmacological
Ginko T.D .
54006
Intervention_Pharmacological
Ginkgo biloba to risperidone
54007
Outcome_Mental
Aberrant Behavior Checklist-Community ( ABC-C ) rating scale
54008
Outcome_Physical
and the
54009
Outcome_Mental
side effect check list
54010
Outcome_Mental
ABC-C rating scale
54011
Outcome_Physical
Incidents of side effects
54012
Participant_Condition
patients with autistic disorders .
54013
Participant_Condition
Autism Spectrum Disorder .
54014
Participant_Sample-size
Forty-seven
54015
Participant_Condition
DSM-IV-TR diagnosis of autism
54016
Participant_Age
ages between 4 and 12 years
54017
Participant_Condition
patients under 30 kg
54018
Participant_Condition
patients above 30 kg .